enGene (ENGN) Projected to Post Earnings on Monday

enGene (NASDAQ:ENGN) is expected to post its Q1 2026 results before the market opens on Monday, March 9th. Analysts expect enGene to post earnings of ($0.55) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Price Performance

Shares of NASDAQ ENGN opened at $8.68 on Friday. The stock has a market capitalization of $581.47 million, a price-to-earnings ratio of -3.79 and a beta of -0.29. The business has a 50-day moving average of $9.58 and a 200-day moving average of $8.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $12.25.

Institutional Trading of enGene

Several hedge funds and other institutional investors have recently modified their holdings of ENGN. Siren L.L.C. bought a new position in enGene in the 4th quarter valued at about $30,126,000. Braidwell LP grew its position in shares of enGene by 38.2% in the fourth quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after purchasing an additional 865,000 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of enGene during the fourth quarter worth approximately $17,110,000. MPM Bioimpact LLC boosted its stake in enGene by 247.1% in the 4th quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock valued at $16,623,000 after purchasing an additional 1,310,599 shares during the period. Finally, Millennium Management LLC grew its holdings in enGene by 7,214.0% in the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock valued at $13,541,000 after buying an additional 1,479,018 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ENGN. Citizens Jmp increased their price target on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. Morgan Stanley increased their price objective on enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, November 12th. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective for the company in a research report on Tuesday, November 11th. Citigroup restated a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price objective (up from $30.00) on shares of enGene in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.29.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.